nodes	percent_of_prediction	percent_of_DWPC	metapath
Cladribine—ABCG2—Vandetanib—thyroid cancer	0.149	0.508	CbGbCtD
Cladribine—ABCG2—Sorafenib—thyroid cancer	0.0901	0.306	CbGbCtD
Cladribine—ABCG2—Doxorubicin—thyroid cancer	0.0547	0.186	CbGbCtD
Cladribine—RRM1—larynx—thyroid cancer	0.0195	0.127	CbGeAlD
Cladribine—POLE4—head—thyroid cancer	0.00861	0.0561	CbGeAlD
Cladribine—RRM2B—saliva-secreting gland—thyroid cancer	0.00816	0.0532	CbGeAlD
Cladribine—POLE3—saliva-secreting gland—thyroid cancer	0.00771	0.0503	CbGeAlD
Cladribine—RRM2B—trachea—thyroid cancer	0.00629	0.041	CbGeAlD
Cladribine—POLE3—trachea—thyroid cancer	0.00595	0.0388	CbGeAlD
Cladribine—POLE—saliva-secreting gland—thyroid cancer	0.00588	0.0384	CbGeAlD
Cladribine—SLC28A3—trachea—thyroid cancer	0.00557	0.0363	CbGeAlD
Cladribine—POLE2—lymph node—thyroid cancer	0.00527	0.0343	CbGeAlD
Cladribine—RRM2B—thyroid gland—thyroid cancer	0.00498	0.0325	CbGeAlD
Cladribine—PNP—head—thyroid cancer	0.00476	0.031	CbGeAlD
Cladribine—POLE3—thyroid gland—thyroid cancer	0.00471	0.0307	CbGeAlD
Cladribine—POLE—trachea—thyroid cancer	0.00454	0.0296	CbGeAlD
Cladribine—RRM2B—head—thyroid cancer	0.00442	0.0288	CbGeAlD
Cladribine—POLE3—head—thyroid cancer	0.00418	0.0272	CbGeAlD
Cladribine—NR5A1—head—thyroid cancer	0.00405	0.0264	CbGeAlD
Cladribine—POLE—thyroid gland—thyroid cancer	0.00359	0.0234	CbGeAlD
Cladribine—POLE—head—thyroid cancer	0.00319	0.0208	CbGeAlD
Cladribine—DCK—saliva-secreting gland—thyroid cancer	0.00313	0.0204	CbGeAlD
Cladribine—POLA1—thyroid gland—thyroid cancer	0.00309	0.0202	CbGeAlD
Cladribine—RRM2B—lymph node—thyroid cancer	0.00309	0.0202	CbGeAlD
Cladribine—RRM2—thyroid gland—thyroid cancer	0.00296	0.0193	CbGeAlD
Cladribine—POLE3—lymph node—thyroid cancer	0.00292	0.0191	CbGeAlD
Cladribine—RRM2—head—thyroid cancer	0.00262	0.0171	CbGeAlD
Cladribine—RRM1—thyroid gland—thyroid cancer	0.00246	0.016	CbGeAlD
Cladribine—DCK—trachea—thyroid cancer	0.00241	0.0157	CbGeAlD
Cladribine—POLE—lymph node—thyroid cancer	0.00223	0.0145	CbGeAlD
Cladribine—RRM1—head—thyroid cancer	0.00218	0.0142	CbGeAlD
Cladribine—PNP—Erlotinib—Vandetanib—thyroid cancer	0.00207	0.163	CbGdCrCtD
Cladribine—POLA1—lymph node—thyroid cancer	0.00192	0.0125	CbGeAlD
Cladribine—DCK—thyroid gland—thyroid cancer	0.00191	0.0124	CbGeAlD
Cladribine—RRM2—lymph node—thyroid cancer	0.00184	0.012	CbGeAlD
Cladribine—POLE2—Afatinib—Vandetanib—thyroid cancer	0.00175	0.138	CbGdCrCtD
Cladribine—ABCG2—saliva-secreting gland—thyroid cancer	0.00174	0.0114	CbGeAlD
Cladribine—DCK—head—thyroid cancer	0.00169	0.011	CbGeAlD
Cladribine—RRM1—lymph node—thyroid cancer	0.00153	0.00995	CbGeAlD
Cladribine—SLC22A1—head—thyroid cancer	0.00144	0.00941	CbGeAlD
Cladribine—RRM2—Afatinib—Vandetanib—thyroid cancer	0.00139	0.11	CbGdCrCtD
Cladribine—PNP—Afatinib—Vandetanib—thyroid cancer	0.00135	0.107	CbGdCrCtD
Cladribine—RRM2—Gefitinib—Vandetanib—thyroid cancer	0.00122	0.0961	CbGdCrCtD
Cladribine—DCK—lymph node—thyroid cancer	0.00119	0.00773	CbGeAlD
Cladribine—PNP—Gefitinib—Vandetanib—thyroid cancer	0.00118	0.0934	CbGdCrCtD
Cladribine—ABCG2—thyroid gland—thyroid cancer	0.00106	0.00694	CbGeAlD
Cladribine—RRM2B—miRNA Regulation of DNA Damage Response—TP53—thyroid cancer	0.00084	0.00422	CbGpPWpGaD
Cladribine—POLA1—E2F transcription factor network—CDK1—thyroid cancer	0.00084	0.00422	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—CHST14—thyroid cancer	0.000822	0.00414	CbGpPWpGaD
Cladribine—POLE2—Mitotic M-M/G1 phases—TPR—thyroid cancer	0.000809	0.00407	CbGpPWpGaD
Cladribine—POLE2—G1 to S cell cycle control—CCND1—thyroid cancer	0.000806	0.00406	CbGpPWpGaD
Cladribine—POLE—Telomere Maintenance—TERT—thyroid cancer	0.000806	0.00405	CbGpPWpGaD
Cladribine—RRM1—Fluoropyrimidine Activity—TP53—thyroid cancer	0.000772	0.00388	CbGpPWpGaD
Cladribine—PNP—Metabolism—NDUFA13—thyroid cancer	0.000758	0.00381	CbGpPWpGaD
Cladribine—RRM2—Mitotic G1-G1/S phases—CDK1—thyroid cancer	0.000751	0.00378	CbGpPWpGaD
Cladribine—ABCG2—HIF-1-alpha transcription factor network—CP—thyroid cancer	0.000735	0.00369	CbGpPWpGaD
Cladribine—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—EPO—thyroid cancer	0.000732	0.00368	CbGpPWpGaD
Cladribine—SLC28A3—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.000731	0.00368	CbGpPWpGaD
Cladribine—POLA1—Retinoblastoma (RB) in Cancer—CDK1—thyroid cancer	0.00073	0.00367	CbGpPWpGaD
Cladribine—POLE—Mitotic G1-G1/S phases—CDK1—thyroid cancer	0.000721	0.00362	CbGpPWpGaD
Cladribine—RRM2B—Direct p53 effectors—PTEN—thyroid cancer	0.000715	0.0036	CbGpPWpGaD
Cladribine—PNP—Metabolism—CHST14—thyroid cancer	0.000713	0.00359	CbGpPWpGaD
Cladribine—POLE—Chromosome Maintenance—TERT—thyroid cancer	0.000671	0.00338	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—PCM1—thyroid cancer	0.000665	0.00335	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—HPGD—thyroid cancer	0.000663	0.00333	CbGpPWpGaD
Cladribine—POLE2—Retinoblastoma (RB) in Cancer—CCND1—thyroid cancer	0.000662	0.00333	CbGpPWpGaD
Cladribine—ABCG2—lymph node—thyroid cancer	0.000661	0.00431	CbGeAlD
Cladribine—Blood bilirubin increased—Epirubicin—thyroid cancer	0.000655	0.00192	CcSEcCtD
Cladribine—Bone pain—Epirubicin—thyroid cancer	0.000647	0.0019	CcSEcCtD
Cladribine—NR5A1—Gene Expression—TRIM33—thyroid cancer	0.000646	0.00325	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	0.000641	0.00322	CbGpPWpGaD
Cladribine—Cough—Sorafenib—thyroid cancer	0.00064	0.00188	CcSEcCtD
Cladribine—Inflammation—Epirubicin—thyroid cancer	0.000639	0.00187	CcSEcCtD
Cladribine—POLE—Cell Cycle, Mitotic—PCM1—thyroid cancer	0.000639	0.00321	CbGpPWpGaD
Cladribine—Asthenia—Vandetanib—thyroid cancer	0.000637	0.00187	CcSEcCtD
Cladribine—RRM2—Fluoropyrimidine Activity—TP53—thyroid cancer	0.000636	0.0032	CbGpPWpGaD
Cladribine—Bone disorder—Doxorubicin—thyroid cancer	0.000635	0.00186	CcSEcCtD
Cladribine—Blood uric acid increased—Epirubicin—thyroid cancer	0.000631	0.00185	CcSEcCtD
Cladribine—Cellulitis—Doxorubicin—thyroid cancer	0.000631	0.00185	CcSEcCtD
Cladribine—Pruritus—Vandetanib—thyroid cancer	0.000628	0.00184	CcSEcCtD
Cladribine—Musculoskeletal pain—Epirubicin—thyroid cancer	0.000627	0.00184	CcSEcCtD
Cladribine—Myalgia—Sorafenib—thyroid cancer	0.000624	0.00183	CcSEcCtD
Cladribine—Arthralgia—Sorafenib—thyroid cancer	0.000624	0.00183	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00062	0.00182	CcSEcCtD
Cladribine—Pulmonary embolism—Epirubicin—thyroid cancer	0.00062	0.00182	CcSEcCtD
Cladribine—Hyperuricaemia—Doxorubicin—thyroid cancer	0.000618	0.00181	CcSEcCtD
Cladribine—Injection site reaction—Epirubicin—thyroid cancer	0.000616	0.00181	CcSEcCtD
Cladribine—NR5A1—Generic Transcription Pathway—MEN1—thyroid cancer	0.000616	0.0031	CbGpPWpGaD
Cladribine—POLA1—G1/S Transition—CDK1—thyroid cancer	0.000609	0.00306	CbGpPWpGaD
Cladribine—Diarrhoea—Vandetanib—thyroid cancer	0.000607	0.00178	CcSEcCtD
Cladribine—Blood bilirubin increased—Doxorubicin—thyroid cancer	0.000606	0.00178	CcSEcCtD
Cladribine—POLE2—Cell Cycle, Mitotic—TPR—thyroid cancer	0.000605	0.00304	CbGpPWpGaD
Cladribine—Bone pain—Doxorubicin—thyroid cancer	0.000599	0.00176	CcSEcCtD
Cladribine—RRM2—Cell Cycle—PCM1—thyroid cancer	0.000595	0.00299	CbGpPWpGaD
Cladribine—Infection—Sorafenib—thyroid cancer	0.000595	0.00174	CcSEcCtD
Cladribine—Candida infection—Epirubicin—thyroid cancer	0.000592	0.00174	CcSEcCtD
Cladribine—Inflammation—Doxorubicin—thyroid cancer	0.000591	0.00173	CcSEcCtD
Cladribine—Nervous system disorder—Sorafenib—thyroid cancer	0.000587	0.00172	CcSEcCtD
Cladribine—Dizziness—Vandetanib—thyroid cancer	0.000587	0.00172	CcSEcCtD
Cladribine—Thrombocytopenia—Sorafenib—thyroid cancer	0.000586	0.00172	CcSEcCtD
Cladribine—Blood uric acid increased—Doxorubicin—thyroid cancer	0.000584	0.00171	CcSEcCtD
Cladribine—Aplastic anaemia—Epirubicin—thyroid cancer	0.000582	0.00171	CcSEcCtD
Cladribine—Skin disorder—Sorafenib—thyroid cancer	0.000581	0.00171	CcSEcCtD
Cladribine—Musculoskeletal pain—Doxorubicin—thyroid cancer	0.000581	0.0017	CcSEcCtD
Cladribine—ABCG2—HIF-1-alpha transcription factor network—EPO—thyroid cancer	0.000576	0.0029	CbGpPWpGaD
Cladribine—PNP—Metabolism—HPGD—thyroid cancer	0.000575	0.00289	CbGpPWpGaD
Cladribine—POLA1—Telomere Maintenance—TERT—thyroid cancer	0.000574	0.00289	CbGpPWpGaD
Cladribine—Pulmonary embolism—Doxorubicin—thyroid cancer	0.000574	0.00168	CcSEcCtD
Cladribine—POLE—Cell Cycle—PCM1—thyroid cancer	0.000571	0.00287	CbGpPWpGaD
Cladribine—Anorexia—Sorafenib—thyroid cancer	0.00057	0.00167	CcSEcCtD
Cladribine—Injection site reaction—Doxorubicin—thyroid cancer	0.00057	0.00167	CcSEcCtD
Cladribine—Vomiting—Vandetanib—thyroid cancer	0.000564	0.00165	CcSEcCtD
Cladribine—Neoplasm—Epirubicin—thyroid cancer	0.00056	0.00164	CcSEcCtD
Cladribine—Ecchymosis—Epirubicin—thyroid cancer	0.00056	0.00164	CcSEcCtD
Cladribine—Rash—Vandetanib—thyroid cancer	0.000559	0.00164	CcSEcCtD
Cladribine—Dermatitis—Vandetanib—thyroid cancer	0.000559	0.00164	CcSEcCtD
Cladribine—Headache—Vandetanib—thyroid cancer	0.000556	0.00163	CcSEcCtD
Cladribine—POLE2—Mitotic M-M/G1 phases—CDK1—thyroid cancer	0.000548	0.00276	CbGpPWpGaD
Cladribine—Candida infection—Doxorubicin—thyroid cancer	0.000548	0.00161	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.000545	0.0016	CcSEcCtD
Cladribine—POLE2—Cell Cycle—TPR—thyroid cancer	0.000541	0.00272	CbGpPWpGaD
Cladribine—RRM1—Retinoblastoma (RB) in Cancer—CCND1—thyroid cancer	0.00054	0.00271	CbGpPWpGaD
Cladribine—Aplastic anaemia—Doxorubicin—thyroid cancer	0.000539	0.00158	CcSEcCtD
Cladribine—Sepsis—Epirubicin—thyroid cancer	0.000538	0.00158	CcSEcCtD
Cladribine—SLC22A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—thyroid cancer	0.000534	0.00269	CbGpPWpGaD
Cladribine—Dyspnoea—Sorafenib—thyroid cancer	0.000534	0.00157	CcSEcCtD
Cladribine—POLE2—G1 to S cell cycle control—TP53—thyroid cancer	0.000531	0.00267	CbGpPWpGaD
Cladribine—Nausea—Vandetanib—thyroid cancer	0.000527	0.00155	CcSEcCtD
Cladribine—Phlebitis—Epirubicin—thyroid cancer	0.000522	0.00153	CcSEcCtD
Cladribine—POLE—Mitotic M-M/G1 phases—TPR—thyroid cancer	0.000522	0.00262	CbGpPWpGaD
Cladribine—Decreased appetite—Sorafenib—thyroid cancer	0.00052	0.00153	CcSEcCtD
Cladribine—POLE—G1 to S cell cycle control—CCND1—thyroid cancer	0.00052	0.00261	CbGpPWpGaD
Cladribine—Neoplasm—Doxorubicin—thyroid cancer	0.000519	0.00152	CcSEcCtD
Cladribine—Ecchymosis—Doxorubicin—thyroid cancer	0.000519	0.00152	CcSEcCtD
Cladribine—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000517	0.00152	CcSEcCtD
Cladribine—Fatigue—Sorafenib—thyroid cancer	0.000516	0.00151	CcSEcCtD
Cladribine—POLA1—Mitotic G1-G1/S phases—CDK1—thyroid cancer	0.000514	0.00258	CbGpPWpGaD
Cladribine—RRM1—Metabolism—MINPP1—thyroid cancer	0.000512	0.00258	CbGpPWpGaD
Cladribine—Constipation—Sorafenib—thyroid cancer	0.000512	0.0015	CcSEcCtD
Cladribine—Pain—Sorafenib—thyroid cancer	0.000512	0.0015	CcSEcCtD
Cladribine—Vascular purpura—Epirubicin—thyroid cancer	0.000503	0.00148	CcSEcCtD
Cladribine—POLE2—S Phase—CCND1—thyroid cancer	0.000502	0.00252	CbGpPWpGaD
Cladribine—Hepatic failure—Epirubicin—thyroid cancer	0.000501	0.00147	CcSEcCtD
Cladribine—SLC22A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—thyroid cancer	0.000498	0.0025	CbGpPWpGaD
Cladribine—Sepsis—Doxorubicin—thyroid cancer	0.000498	0.00146	CcSEcCtD
Cladribine—SLC28A3—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000497	0.0025	CbGpPWpGaD
Cladribine—SLC28A3—Transmembrane transport of small molecules—CP—thyroid cancer	0.000497	0.0025	CbGpPWpGaD
Cladribine—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000489	0.00144	CcSEcCtD
Cladribine—SLC28A3—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000488	0.00246	CbGpPWpGaD
Cladribine—RRM2B—Direct p53 effectors—TP53—thyroid cancer	0.000488	0.00245	CbGpPWpGaD
Cladribine—Renal failure acute—Epirubicin—thyroid cancer	0.000487	0.00143	CcSEcCtD
Cladribine—Phlebitis—Doxorubicin—thyroid cancer	0.000483	0.00142	CcSEcCtD
Cladribine—POLA1—Chromosome Maintenance—TERT—thyroid cancer	0.000478	0.00241	CbGpPWpGaD
Cladribine—Urticaria—Sorafenib—thyroid cancer	0.000475	0.00139	CcSEcCtD
Cladribine—Body temperature increased—Sorafenib—thyroid cancer	0.000473	0.00139	CcSEcCtD
Cladribine—Abdominal pain—Sorafenib—thyroid cancer	0.000473	0.00139	CcSEcCtD
Cladribine—Renal impairment—Epirubicin—thyroid cancer	0.000473	0.00139	CcSEcCtD
Cladribine—NR5A1—Gene Expression—THRB—thyroid cancer	0.000467	0.00235	CbGpPWpGaD
Cladribine—Purpura—Epirubicin—thyroid cancer	0.000467	0.00137	CcSEcCtD
Cladribine—POLE2—Mitotic G1-G1/S phases—CCND1—thyroid cancer	0.000466	0.00234	CbGpPWpGaD
Cladribine—Vascular purpura—Doxorubicin—thyroid cancer	0.000465	0.00137	CcSEcCtD
Cladribine—Hepatic failure—Doxorubicin—thyroid cancer	0.000463	0.00136	CcSEcCtD
Cladribine—Cardiac failure—Epirubicin—thyroid cancer	0.000461	0.00135	CcSEcCtD
Cladribine—Lethargy—Epirubicin—thyroid cancer	0.000459	0.00135	CcSEcCtD
Cladribine—Cerebrovascular accident—Epirubicin—thyroid cancer	0.000459	0.00135	CcSEcCtD
Cladribine—POLA1—Cell Cycle, Mitotic—PCM1—thyroid cancer	0.000455	0.00229	CbGpPWpGaD
Cladribine—POLE2—Daunorubicin—Epirubicin—thyroid cancer	0.000454	0.0359	CbGdCrCtD
Cladribine—POLE2—Doxorubicin—Epirubicin—thyroid cancer	0.000454	0.0359	CbGdCrCtD
Cladribine—POLE2—Idarubicin—Epirubicin—thyroid cancer	0.000454	0.0359	CbGdCrCtD
Cladribine—Renal failure acute—Doxorubicin—thyroid cancer	0.000451	0.00132	CcSEcCtD
Cladribine—Pain in extremity—Epirubicin—thyroid cancer	0.00045	0.00132	CcSEcCtD
Cladribine—RRM2—Retinoblastoma (RB) in Cancer—CCND1—thyroid cancer	0.000445	0.00224	CbGpPWpGaD
Cladribine—Hypersensitivity—Sorafenib—thyroid cancer	0.000441	0.00129	CcSEcCtD
Cladribine—Renal impairment—Doxorubicin—thyroid cancer	0.000438	0.00128	CcSEcCtD
Cladribine—POLE2—Retinoblastoma (RB) in Cancer—TP53—thyroid cancer	0.000436	0.00219	CbGpPWpGaD
Cladribine—RRM1—Metabolism—NDUFA13—thyroid cancer	0.000436	0.00219	CbGpPWpGaD
Cladribine—Purpura—Doxorubicin—thyroid cancer	0.000432	0.00127	CcSEcCtD
Cladribine—Asthenia—Sorafenib—thyroid cancer	0.000429	0.00126	CcSEcCtD
Cladribine—POLE—Retinoblastoma (RB) in Cancer—CCND1—thyroid cancer	0.000427	0.00215	CbGpPWpGaD
Cladribine—Cardiac failure—Doxorubicin—thyroid cancer	0.000427	0.00125	CcSEcCtD
Cladribine—Lethargy—Doxorubicin—thyroid cancer	0.000425	0.00125	CcSEcCtD
Cladribine—Cerebrovascular accident—Doxorubicin—thyroid cancer	0.000425	0.00125	CcSEcCtD
Cladribine—Pruritus—Sorafenib—thyroid cancer	0.000423	0.00124	CcSEcCtD
Cladribine—Ataxia—Epirubicin—thyroid cancer	0.000423	0.00124	CcSEcCtD
Cladribine—RRM2—Metabolism—MINPP1—thyroid cancer	0.000422	0.00212	CbGpPWpGaD
Cladribine—POLE2—Daunorubicin—Doxorubicin—thyroid cancer	0.00042	0.0332	CbGdCrCtD
Cladribine—POLE2—Epirubicin—Doxorubicin—thyroid cancer	0.00042	0.0332	CbGdCrCtD
Cladribine—POLE2—Idarubicin—Doxorubicin—thyroid cancer	0.00042	0.0332	CbGdCrCtD
Cladribine—NR5A1—Developmental Biology—CDK1—thyroid cancer	0.000418	0.0021	CbGpPWpGaD
Cladribine—Pain in extremity—Doxorubicin—thyroid cancer	0.000416	0.00122	CcSEcCtD
Cladribine—DCK—Retinoblastoma (RB) in Cancer—CCND1—thyroid cancer	0.000415	0.00209	CbGpPWpGaD
Cladribine—NR5A1—Generic Transcription Pathway—RXRA—thyroid cancer	0.000412	0.00207	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle, Mitotic—CDK1—thyroid cancer	0.00041	0.00206	CbGpPWpGaD
Cladribine—RRM1—Metabolism—CHST14—thyroid cancer	0.000409	0.00206	CbGpPWpGaD
Cladribine—Diarrhoea—Sorafenib—thyroid cancer	0.000409	0.0012	CcSEcCtD
Cladribine—POLA1—Cell Cycle—PCM1—thyroid cancer	0.000407	0.00205	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—TPR—thyroid cancer	0.000406	0.00204	CbGpPWpGaD
Cladribine—Toxic epidermal necrolysis—Epirubicin—thyroid cancer	0.000405	0.00119	CcSEcCtD
Cladribine—Muscular weakness—Epirubicin—thyroid cancer	0.000397	0.00116	CcSEcCtD
Cladribine—Dizziness—Sorafenib—thyroid cancer	0.000396	0.00116	CcSEcCtD
Cladribine—DCK—Metabolism—MINPP1—thyroid cancer	0.000394	0.00198	CbGpPWpGaD
Cladribine—Ataxia—Doxorubicin—thyroid cancer	0.000392	0.00115	CcSEcCtD
Cladribine—POLE—Cell Cycle, Mitotic—TPR—thyroid cancer	0.00039	0.00196	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—RXRA—thyroid cancer	0.000388	0.00195	CbGpPWpGaD
Cladribine—Eosinophilia—Epirubicin—thyroid cancer	0.000385	0.00113	CcSEcCtD
Cladribine—RRM2B—Metabolism—TPR—thyroid cancer	0.000381	0.00191	CbGpPWpGaD
Cladribine—Vomiting—Sorafenib—thyroid cancer	0.000381	0.00112	CcSEcCtD
Cladribine—Rash—Sorafenib—thyroid cancer	0.000377	0.00111	CcSEcCtD
Cladribine—Dermatitis—Sorafenib—thyroid cancer	0.000377	0.00111	CcSEcCtD
Cladribine—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	0.000375	0.0011	CcSEcCtD
Cladribine—Headache—Sorafenib—thyroid cancer	0.000375	0.0011	CcSEcCtD
Cladribine—RRM2B—Metabolism—PRKAR1A—thyroid cancer	0.000375	0.00188	CbGpPWpGaD
Cladribine—SLC28A3—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000372	0.00187	CbGpPWpGaD
Cladribine—POLA1—Mitotic M-M/G1 phases—TPR—thyroid cancer	0.000372	0.00187	CbGpPWpGaD
Cladribine—Pancytopenia—Epirubicin—thyroid cancer	0.000369	0.00108	CcSEcCtD
Cladribine—Muscular weakness—Doxorubicin—thyroid cancer	0.000367	0.00108	CcSEcCtD
Cladribine—POLE2—Cell Cycle—CDK1—thyroid cancer	0.000367	0.00184	CbGpPWpGaD
Cladribine—Neutropenia—Epirubicin—thyroid cancer	0.000364	0.00107	CcSEcCtD
Cladribine—RRM2—Cell Cycle—TPR—thyroid cancer	0.000363	0.00183	CbGpPWpGaD
Cladribine—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.000361	0.00106	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	0.000361	0.00182	CbGpPWpGaD
Cladribine—ABCG2—HIF-1-alpha transcription factor network—TERT—thyroid cancer	0.000359	0.0018	CbGpPWpGaD
Cladribine—RRM2—Metabolism—NDUFA13—thyroid cancer	0.000359	0.0018	CbGpPWpGaD
Cladribine—Eosinophilia—Doxorubicin—thyroid cancer	0.000356	0.00105	CcSEcCtD
Cladribine—RRM1—Retinoblastoma (RB) in Cancer—TP53—thyroid cancer	0.000356	0.00179	CbGpPWpGaD
Cladribine—Nausea—Sorafenib—thyroid cancer	0.000355	0.00104	CcSEcCtD
Cladribine—POLE—Mitotic M-M/G1 phases—CDK1—thyroid cancer	0.000353	0.00178	CbGpPWpGaD
Cladribine—PNP—Daunorubicin—Epirubicin—thyroid cancer	0.00035	0.0277	CbGdCrCtD
Cladribine—POLE—Cell Cycle—TPR—thyroid cancer	0.000349	0.00175	CbGpPWpGaD
Cladribine—Pneumonia—Epirubicin—thyroid cancer	0.000349	0.00102	CcSEcCtD
Cladribine—Infestation—Epirubicin—thyroid cancer	0.000347	0.00102	CcSEcCtD
Cladribine—Infestation NOS—Epirubicin—thyroid cancer	0.000347	0.00102	CcSEcCtD
Cladribine—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.000344	0.00101	CcSEcCtD
Cladribine—ABCG2—HIF-1-alpha transcription factor network—HIF1A—thyroid cancer	0.000343	0.00173	CbGpPWpGaD
Cladribine—POLE—G1 to S cell cycle control—TP53—thyroid cancer	0.000342	0.00172	CbGpPWpGaD
Cladribine—Pancytopenia—Doxorubicin—thyroid cancer	0.000342	0.001	CcSEcCtD
Cladribine—Renal failure—Epirubicin—thyroid cancer	0.000341	0.001	CcSEcCtD
Cladribine—RRM2—Metabolism—CHST14—thyroid cancer	0.000337	0.0017	CbGpPWpGaD
Cladribine—Urinary tract infection—Epirubicin—thyroid cancer	0.000337	0.000989	CcSEcCtD
Cladribine—Conjunctivitis—Epirubicin—thyroid cancer	0.000337	0.000989	CcSEcCtD
Cladribine—Neutropenia—Doxorubicin—thyroid cancer	0.000337	0.000987	CcSEcCtD
Cladribine—DCK—Metabolism—NDUFA13—thyroid cancer	0.000335	0.00169	CbGpPWpGaD
Cladribine—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.000334	0.000981	CcSEcCtD
Cladribine—PNP—Metabolism—TPR—thyroid cancer	0.00033	0.00166	CbGpPWpGaD
Cladribine—RRM1—Metabolism—HPGD—thyroid cancer	0.00033	0.00166	CbGpPWpGaD
Cladribine—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000328	0.000962	CcSEcCtD
Cladribine—Epistaxis—Epirubicin—thyroid cancer	0.000327	0.00096	CcSEcCtD
Cladribine—PNP—Metabolism—PRKAR1A—thyroid cancer	0.000325	0.00163	CbGpPWpGaD
Cladribine—PNP—Daunorubicin—Doxorubicin—thyroid cancer	0.000324	0.0256	CbGdCrCtD
Cladribine—POLE—S Phase—CCND1—thyroid cancer	0.000323	0.00163	CbGpPWpGaD
Cladribine—Pneumonia—Doxorubicin—thyroid cancer	0.000323	0.000947	CcSEcCtD
Cladribine—Infestation—Doxorubicin—thyroid cancer	0.000321	0.000941	CcSEcCtD
Cladribine—Infestation NOS—Doxorubicin—thyroid cancer	0.000321	0.000941	CcSEcCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	0.000318	0.0016	CbGpPWpGaD
Cladribine—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.000318	0.000933	CcSEcCtD
Cladribine—NR5A1—Gene Expression—TPR—thyroid cancer	0.000315	0.00159	CbGpPWpGaD
Cladribine—Renal failure—Doxorubicin—thyroid cancer	0.000315	0.000925	CcSEcCtD
Cladribine—DCK—Metabolism—CHST14—thyroid cancer	0.000315	0.00158	CbGpPWpGaD
Cladribine—Haemoglobin—Epirubicin—thyroid cancer	0.000313	0.000918	CcSEcCtD
Cladribine—RRM2—Mitotic G1-G1/S phases—CCND1—thyroid cancer	0.000313	0.00157	CbGpPWpGaD
Cladribine—SLC28A3—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000312	0.00157	CbGpPWpGaD
Cladribine—Conjunctivitis—Doxorubicin—thyroid cancer	0.000312	0.000915	CcSEcCtD
Cladribine—Urinary tract infection—Doxorubicin—thyroid cancer	0.000312	0.000915	CcSEcCtD
Cladribine—Haemorrhage—Epirubicin—thyroid cancer	0.000311	0.000913	CcSEcCtD
Cladribine—Pharyngitis—Epirubicin—thyroid cancer	0.000309	0.000906	CcSEcCtD
Cladribine—Urinary tract disorder—Epirubicin—thyroid cancer	0.000307	0.000902	CcSEcCtD
Cladribine—Oedema peripheral—Epirubicin—thyroid cancer	0.000307	0.0009	CcSEcCtD
Cladribine—Connective tissue disorder—Epirubicin—thyroid cancer	0.000306	0.000897	CcSEcCtD
Cladribine—Urethral disorder—Epirubicin—thyroid cancer	0.000305	0.000895	CcSEcCtD
Cladribine—POLA1—Retinoblastoma (RB) in Cancer—CCND1—thyroid cancer	0.000304	0.00153	CbGpPWpGaD
Cladribine—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.000303	0.00089	CcSEcCtD
Cladribine—Epistaxis—Doxorubicin—thyroid cancer	0.000303	0.000888	CcSEcCtD
Cladribine—POLE—Mitotic G1-G1/S phases—CCND1—thyroid cancer	0.0003	0.00151	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—MEN1—thyroid cancer	0.000297	0.00149	CbGpPWpGaD
Cladribine—Erythema multiforme—Epirubicin—thyroid cancer	0.000294	0.000863	CcSEcCtD
Cladribine—RRM2—Retinoblastoma (RB) in Cancer—TP53—thyroid cancer	0.000293	0.00147	CbGpPWpGaD
Cladribine—Eye disorder—Epirubicin—thyroid cancer	0.000291	0.000853	CcSEcCtD
Cladribine—Haemoglobin—Doxorubicin—thyroid cancer	0.00029	0.000849	CcSEcCtD
Cladribine—Cardiac disorder—Epirubicin—thyroid cancer	0.000289	0.000848	CcSEcCtD
Cladribine—Haemorrhage—Doxorubicin—thyroid cancer	0.000288	0.000845	CcSEcCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	0.000288	0.00145	CbGpPWpGaD
Cladribine—Pharyngitis—Doxorubicin—thyroid cancer	0.000286	0.000839	CcSEcCtD
Cladribine—RRM2B—Metabolism—SLC5A5—thyroid cancer	0.000285	0.00143	CbGpPWpGaD
Cladribine—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000284	0.000835	CcSEcCtD
Cladribine—Oedema peripheral—Doxorubicin—thyroid cancer	0.000284	0.000832	CcSEcCtD
Cladribine—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000283	0.00083	CcSEcCtD
Cladribine—Angiopathy—Epirubicin—thyroid cancer	0.000282	0.000829	CcSEcCtD
Cladribine—Urethral disorder—Doxorubicin—thyroid cancer	0.000282	0.000828	CcSEcCtD
Cladribine—Immune system disorder—Epirubicin—thyroid cancer	0.000281	0.000825	CcSEcCtD
Cladribine—POLE—Retinoblastoma (RB) in Cancer—TP53—thyroid cancer	0.000281	0.00141	CbGpPWpGaD
Cladribine—Mediastinal disorder—Epirubicin—thyroid cancer	0.000281	0.000823	CcSEcCtD
Cladribine—Chills—Epirubicin—thyroid cancer	0.000279	0.000819	CcSEcCtD
Cladribine—Arrhythmia—Epirubicin—thyroid cancer	0.000278	0.000816	CcSEcCtD
Cladribine—POLA1—Cell Cycle, Mitotic—TPR—thyroid cancer	0.000278	0.0014	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	0.000278	0.0014	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—CDK1—thyroid cancer	0.000275	0.00138	CbGpPWpGaD
Cladribine—Alopecia—Epirubicin—thyroid cancer	0.000275	0.000807	CcSEcCtD
Cladribine—DCK—Retinoblastoma (RB) in Cancer—TP53—thyroid cancer	0.000274	0.00138	CbGpPWpGaD
Cladribine—Mental disorder—Epirubicin—thyroid cancer	0.000273	0.0008	CcSEcCtD
Cladribine—Erythema multiforme—Doxorubicin—thyroid cancer	0.000272	0.000799	CcSEcCtD
Cladribine—RRM2—Metabolism—HPGD—thyroid cancer	0.000272	0.00137	CbGpPWpGaD
Cladribine—Malnutrition—Epirubicin—thyroid cancer	0.000271	0.000795	CcSEcCtD
Cladribine—Erythema—Epirubicin—thyroid cancer	0.000271	0.000795	CcSEcCtD
Cladribine—Eye disorder—Doxorubicin—thyroid cancer	0.000269	0.00079	CcSEcCtD
Cladribine—Cardiac disorder—Doxorubicin—thyroid cancer	0.000267	0.000784	CcSEcCtD
Cladribine—Flatulence—Epirubicin—thyroid cancer	0.000267	0.000783	CcSEcCtD
Cladribine—POLE2—Cell Cycle—TERT—thyroid cancer	0.000264	0.00133	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—CDK1—thyroid cancer	0.000264	0.00133	CbGpPWpGaD
Cladribine—Back pain—Epirubicin—thyroid cancer	0.000262	0.000769	CcSEcCtD
Cladribine—Angiopathy—Doxorubicin—thyroid cancer	0.000261	0.000767	CcSEcCtD
Cladribine—NR5A1—Generic Transcription Pathway—PPARG—thyroid cancer	0.00026	0.00131	CbGpPWpGaD
Cladribine—Immune system disorder—Doxorubicin—thyroid cancer	0.00026	0.000763	CcSEcCtD
Cladribine—Mediastinal disorder—Doxorubicin—thyroid cancer	0.00026	0.000762	CcSEcCtD
Cladribine—Chills—Doxorubicin—thyroid cancer	0.000258	0.000758	CcSEcCtD
Cladribine—Arrhythmia—Doxorubicin—thyroid cancer	0.000257	0.000755	CcSEcCtD
Cladribine—Alopecia—Doxorubicin—thyroid cancer	0.000255	0.000747	CcSEcCtD
Cladribine—DCK—Metabolism—HPGD—thyroid cancer	0.000254	0.00128	CbGpPWpGaD
Cladribine—Mental disorder—Doxorubicin—thyroid cancer	0.000252	0.00074	CcSEcCtD
Cladribine—POLA1—Mitotic M-M/G1 phases—CDK1—thyroid cancer	0.000252	0.00127	CbGpPWpGaD
Cladribine—Ill-defined disorder—Epirubicin—thyroid cancer	0.000251	0.000738	CcSEcCtD
Cladribine—Erythema—Doxorubicin—thyroid cancer	0.000251	0.000736	CcSEcCtD
Cladribine—Malnutrition—Doxorubicin—thyroid cancer	0.000251	0.000736	CcSEcCtD
Cladribine—Anaemia—Epirubicin—thyroid cancer	0.00025	0.000735	CcSEcCtD
Cladribine—POLA1—Cell Cycle—TPR—thyroid cancer	0.000249	0.00125	CbGpPWpGaD
Cladribine—PNP—Metabolism—SLC5A5—thyroid cancer	0.000247	0.00124	CbGpPWpGaD
Cladribine—Flatulence—Doxorubicin—thyroid cancer	0.000247	0.000725	CcSEcCtD
Cladribine—RRM2—Cell Cycle—CDK1—thyroid cancer	0.000246	0.00124	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—PPARG—thyroid cancer	0.000245	0.00123	CbGpPWpGaD
Cladribine—Malaise—Epirubicin—thyroid cancer	0.000244	0.000717	CcSEcCtD
Cladribine—SLC22A2—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.000243	0.00122	CbGpPWpGaD
Cladribine—SLC22A2—SLC-mediated transmembrane transport—CP—thyroid cancer	0.000243	0.00122	CbGpPWpGaD
Cladribine—Back pain—Doxorubicin—thyroid cancer	0.000243	0.000712	CcSEcCtD
Cladribine—RRM2B—Metabolism—RXRA—thyroid cancer	0.000239	0.0012	CbGpPWpGaD
Cladribine—ABCG2—Fluoropyrimidine Activity—TP53—thyroid cancer	0.000238	0.0012	CbGpPWpGaD
Cladribine—Cough—Epirubicin—thyroid cancer	0.000236	0.000694	CcSEcCtD
Cladribine—POLE—Cell Cycle—CDK1—thyroid cancer	0.000236	0.00119	CbGpPWpGaD
Cladribine—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000233	0.000683	CcSEcCtD
Cladribine—Anaemia—Doxorubicin—thyroid cancer	0.000232	0.00068	CcSEcCtD
Cladribine—Arthralgia—Epirubicin—thyroid cancer	0.000231	0.000677	CcSEcCtD
Cladribine—Myalgia—Epirubicin—thyroid cancer	0.000231	0.000677	CcSEcCtD
Cladribine—Chest pain—Epirubicin—thyroid cancer	0.000231	0.000677	CcSEcCtD
Cladribine—POLA1—S Phase—CCND1—thyroid cancer	0.00023	0.00116	CbGpPWpGaD
Cladribine—Anxiety—Epirubicin—thyroid cancer	0.00023	0.000674	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000229	0.000672	CcSEcCtD
Cladribine—Discomfort—Epirubicin—thyroid cancer	0.000228	0.000669	CcSEcCtD
Cladribine—SLC22A1—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.000226	0.00114	CbGpPWpGaD
Cladribine—SLC22A1—SLC-mediated transmembrane transport—CP—thyroid cancer	0.000226	0.00114	CbGpPWpGaD
Cladribine—Malaise—Doxorubicin—thyroid cancer	0.000226	0.000663	CcSEcCtD
Cladribine—Confusional state—Epirubicin—thyroid cancer	0.000223	0.000654	CcSEcCtD
Cladribine—Oedema—Epirubicin—thyroid cancer	0.000221	0.000649	CcSEcCtD
Cladribine—Infection—Epirubicin—thyroid cancer	0.00022	0.000645	CcSEcCtD
Cladribine—Cough—Doxorubicin—thyroid cancer	0.000219	0.000642	CcSEcCtD
Cladribine—Nervous system disorder—Epirubicin—thyroid cancer	0.000217	0.000636	CcSEcCtD
Cladribine—Thrombocytopenia—Epirubicin—thyroid cancer	0.000217	0.000635	CcSEcCtD
Cladribine—Tachycardia—Epirubicin—thyroid cancer	0.000216	0.000633	CcSEcCtD
Cladribine—Skin disorder—Epirubicin—thyroid cancer	0.000215	0.00063	CcSEcCtD
Cladribine—POLA1—Mitotic G1-G1/S phases—CCND1—thyroid cancer	0.000214	0.00108	CbGpPWpGaD
Cladribine—Hyperhidrosis—Epirubicin—thyroid cancer	0.000214	0.000627	CcSEcCtD
Cladribine—Chest pain—Doxorubicin—thyroid cancer	0.000213	0.000626	CcSEcCtD
Cladribine—Arthralgia—Doxorubicin—thyroid cancer	0.000213	0.000626	CcSEcCtD
Cladribine—Myalgia—Doxorubicin—thyroid cancer	0.000213	0.000626	CcSEcCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	0.000213	0.00107	CbGpPWpGaD
Cladribine—Anxiety—Doxorubicin—thyroid cancer	0.000213	0.000624	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000212	0.000622	CcSEcCtD
Cladribine—Discomfort—Doxorubicin—thyroid cancer	0.000211	0.000619	CcSEcCtD
Cladribine—Anorexia—Epirubicin—thyroid cancer	0.000211	0.000618	CcSEcCtD
Cladribine—PNP—Metabolism—RXRA—thyroid cancer	0.000208	0.00104	CbGpPWpGaD
Cladribine—Hypotension—Epirubicin—thyroid cancer	0.000207	0.000606	CcSEcCtD
Cladribine—Confusional state—Doxorubicin—thyroid cancer	0.000206	0.000605	CcSEcCtD
Cladribine—Oedema—Doxorubicin—thyroid cancer	0.000205	0.0006	CcSEcCtD
Cladribine—DCK—Doxorubicin—Epirubicin—thyroid cancer	0.000205	0.0162	CbGdCrCtD
Cladribine—Infection—Doxorubicin—thyroid cancer	0.000203	0.000596	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000202	0.000591	CcSEcCtD
Cladribine—Nervous system disorder—Doxorubicin—thyroid cancer	0.000201	0.000589	CcSEcCtD
Cladribine—Thrombocytopenia—Doxorubicin—thyroid cancer	0.0002	0.000588	CcSEcCtD
Cladribine—POLA1—Retinoblastoma (RB) in Cancer—TP53—thyroid cancer	0.0002	0.00101	CbGpPWpGaD
Cladribine—Insomnia—Epirubicin—thyroid cancer	0.0002	0.000587	CcSEcCtD
Cladribine—Tachycardia—Doxorubicin—thyroid cancer	0.0002	0.000586	CcSEcCtD
Cladribine—Skin disorder—Doxorubicin—thyroid cancer	0.000199	0.000583	CcSEcCtD
Cladribine—Paraesthesia—Epirubicin—thyroid cancer	0.000199	0.000583	CcSEcCtD
Cladribine—NR5A1—Gene Expression—RXRA—thyroid cancer	0.000198	0.000998	CbGpPWpGaD
Cladribine—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000198	0.00058	CcSEcCtD
Cladribine—Dyspnoea—Epirubicin—thyroid cancer	0.000197	0.000578	CcSEcCtD
Cladribine—Somnolence—Epirubicin—thyroid cancer	0.000197	0.000577	CcSEcCtD
Cladribine—Anorexia—Doxorubicin—thyroid cancer	0.000195	0.000572	CcSEcCtD
Cladribine—Decreased appetite—Epirubicin—thyroid cancer	0.000192	0.000564	CcSEcCtD
Cladribine—Hypotension—Doxorubicin—thyroid cancer	0.000191	0.000561	CcSEcCtD
Cladribine—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000191	0.00056	CcSEcCtD
Cladribine—Fatigue—Epirubicin—thyroid cancer	0.000191	0.000559	CcSEcCtD
Cladribine—RRM1—Metabolism—TPR—thyroid cancer	0.00019	0.000953	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	0.00019	0.000953	CbGpPWpGaD
Cladribine—DCK—Epirubicin—Doxorubicin—thyroid cancer	0.000189	0.015	CbGdCrCtD
Cladribine—Constipation—Epirubicin—thyroid cancer	0.000189	0.000555	CcSEcCtD
Cladribine—Pain—Epirubicin—thyroid cancer	0.000189	0.000555	CcSEcCtD
Cladribine—POLA1—Cell Cycle, Mitotic—CDK1—thyroid cancer	0.000188	0.000947	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PRKAR1A—thyroid cancer	0.000187	0.000938	CbGpPWpGaD
Cladribine—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000186	0.000547	CcSEcCtD
Cladribine—Insomnia—Doxorubicin—thyroid cancer	0.000185	0.000543	CcSEcCtD
Cladribine—Paraesthesia—Doxorubicin—thyroid cancer	0.000184	0.000539	CcSEcCtD
Cladribine—Dyspnoea—Doxorubicin—thyroid cancer	0.000182	0.000535	CcSEcCtD
Cladribine—Feeling abnormal—Epirubicin—thyroid cancer	0.000182	0.000535	CcSEcCtD
Cladribine—Somnolence—Doxorubicin—thyroid cancer	0.000182	0.000534	CcSEcCtD
Cladribine—SLC22A2—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.000182	0.000914	CbGpPWpGaD
Cladribine—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000181	0.000531	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	0.000179	0.000902	CbGpPWpGaD
Cladribine—Decreased appetite—Doxorubicin—thyroid cancer	0.000178	0.000522	CcSEcCtD
Cladribine—RRM2—Cell Cycle—TERT—thyroid cancer	0.000177	0.000892	CbGpPWpGaD
Cladribine—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000177	0.000518	CcSEcCtD
Cladribine—Fatigue—Doxorubicin—thyroid cancer	0.000176	0.000518	CcSEcCtD
Cladribine—Urticaria—Epirubicin—thyroid cancer	0.000176	0.000515	CcSEcCtD
Cladribine—Constipation—Doxorubicin—thyroid cancer	0.000175	0.000513	CcSEcCtD
Cladribine—Pain—Doxorubicin—thyroid cancer	0.000175	0.000513	CcSEcCtD
Cladribine—Body temperature increased—Epirubicin—thyroid cancer	0.000175	0.000513	CcSEcCtD
Cladribine—Abdominal pain—Epirubicin—thyroid cancer	0.000175	0.000513	CcSEcCtD
Cladribine—POLE2—Cell Cycle, Mitotic—CCND1—thyroid cancer	0.000171	0.000859	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—TERT—thyroid cancer	0.00017	0.000857	CbGpPWpGaD
Cladribine—SLC22A1—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.000169	0.000852	CbGpPWpGaD
Cladribine—Feeling abnormal—Doxorubicin—thyroid cancer	0.000169	0.000495	CcSEcCtD
Cladribine—POLA1—Cell Cycle—CDK1—thyroid cancer	0.000168	0.000847	CbGpPWpGaD
Cladribine—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000167	0.000491	CcSEcCtD
Cladribine—Hypersensitivity—Epirubicin—thyroid cancer	0.000163	0.000478	CcSEcCtD
Cladribine—Urticaria—Doxorubicin—thyroid cancer	0.000163	0.000477	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	0.000162	0.000815	CbGpPWpGaD
Cladribine—Body temperature increased—Doxorubicin—thyroid cancer	0.000162	0.000475	CcSEcCtD
Cladribine—Abdominal pain—Doxorubicin—thyroid cancer	0.000162	0.000475	CcSEcCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	0.00016	0.000805	CbGpPWpGaD
Cladribine—Asthenia—Epirubicin—thyroid cancer	0.000159	0.000466	CcSEcCtD
Cladribine—ABCG2—Metabolism—MINPP1—thyroid cancer	0.000158	0.000793	CbGpPWpGaD
Cladribine—Pruritus—Epirubicin—thyroid cancer	0.000156	0.000459	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	0.000156	0.000787	CbGpPWpGaD
Cladribine—RRM2—Metabolism—TPR—thyroid cancer	0.000156	0.000785	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—MINPP1—thyroid cancer	0.000156	0.000785	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PRKAR1A—thyroid cancer	0.000154	0.000772	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—CCND1—thyroid cancer	0.000153	0.000768	CbGpPWpGaD
Cladribine—Diarrhoea—Epirubicin—thyroid cancer	0.000151	0.000444	CcSEcCtD
Cladribine—RRM2B—Metabolism—PPARG—thyroid cancer	0.000151	0.00076	CbGpPWpGaD
Cladribine—Hypersensitivity—Doxorubicin—thyroid cancer	0.000151	0.000442	CcSEcCtD
Cladribine—NR5A1—Developmental Biology—NRAS—thyroid cancer	0.00015	0.000754	CbGpPWpGaD
Cladribine—Asthenia—Doxorubicin—thyroid cancer	0.000147	0.000431	CcSEcCtD
Cladribine—Dizziness—Epirubicin—thyroid cancer	0.000146	0.000429	CcSEcCtD
Cladribine—DCK—Metabolism—TPR—thyroid cancer	0.000146	0.000734	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—MINPP1—thyroid cancer	0.000146	0.000732	CbGpPWpGaD
Cladribine—Pruritus—Doxorubicin—thyroid cancer	0.000145	0.000425	CcSEcCtD
Cladribine—DCK—Metabolism—PRKAR1A—thyroid cancer	0.000144	0.000722	CbGpPWpGaD
Cladribine—RRM1—Metabolism—SLC5A5—thyroid cancer	0.000142	0.000714	CbGpPWpGaD
Cladribine—Vomiting—Epirubicin—thyroid cancer	0.000141	0.000413	CcSEcCtD
Cladribine—Diarrhoea—Doxorubicin—thyroid cancer	0.00014	0.000411	CcSEcCtD
Cladribine—Rash—Epirubicin—thyroid cancer	0.000139	0.000409	CcSEcCtD
Cladribine—Dermatitis—Epirubicin—thyroid cancer	0.000139	0.000409	CcSEcCtD
Cladribine—Headache—Epirubicin—thyroid cancer	0.000139	0.000406	CcSEcCtD
Cladribine—Dizziness—Doxorubicin—thyroid cancer	0.000135	0.000397	CcSEcCtD
Cladribine—ABCG2—Metabolism—NDUFA13—thyroid cancer	0.000134	0.000675	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—NDUFA13—thyroid cancer	0.000133	0.000668	CbGpPWpGaD
Cladribine—Nausea—Epirubicin—thyroid cancer	0.000131	0.000385	CcSEcCtD
Cladribine—PNP—Metabolism—PPARG—thyroid cancer	0.000131	0.000659	CbGpPWpGaD
Cladribine—Vomiting—Doxorubicin—thyroid cancer	0.00013	0.000382	CcSEcCtD
Cladribine—Rash—Doxorubicin—thyroid cancer	0.000129	0.000379	CcSEcCtD
Cladribine—NR5A1—Developmental Biology—KRAS—thyroid cancer	0.000129	0.000649	CbGpPWpGaD
Cladribine—Dermatitis—Doxorubicin—thyroid cancer	0.000129	0.000378	CcSEcCtD
Cladribine—Headache—Doxorubicin—thyroid cancer	0.000128	0.000376	CcSEcCtD
Cladribine—ABCG2—Metabolism—CHST14—thyroid cancer	0.000126	0.000634	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—PPARG—thyroid cancer	0.000125	0.00063	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CHST14—thyroid cancer	0.000125	0.000628	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000125	0.000627	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—CP—thyroid cancer	0.000125	0.000627	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—NDUFA13—thyroid cancer	0.000124	0.000622	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000123	0.00062	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—CP—thyroid cancer	0.000123	0.00062	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000123	0.000617	CbGpPWpGaD
Cladribine—Nausea—Doxorubicin—thyroid cancer	0.000122	0.000357	CcSEcCtD
Cladribine—POLA1—Cell Cycle—TERT—thyroid cancer	0.000121	0.00061	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000121	0.00061	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	0.00012	0.000604	CbGpPWpGaD
Cladribine—RRM1—Metabolism—RXRA—thyroid cancer	0.000119	0.0006	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—PTGS2—thyroid cancer	0.000119	0.000598	CbGpPWpGaD
Cladribine—RRM2—Metabolism—SLC5A5—thyroid cancer	0.000117	0.000588	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CHST14—thyroid cancer	0.000116	0.000585	CbGpPWpGaD
Cladribine—SLC22A2—Transmission across Chemical Synapses—BRAF—thyroid cancer	0.000116	0.000582	CbGpPWpGaD
Cladribine—ABCG2—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	0.000115	0.00058	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—CP—thyroid cancer	0.000115	0.000578	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000115	0.000578	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—CCND1—thyroid cancer	0.000115	0.000577	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000113	0.000569	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—CCND1—thyroid cancer	0.00011	0.000554	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—HRAS—thyroid cancer	0.00011	0.000552	CbGpPWpGaD
Cladribine—DCK—Metabolism—SLC5A5—thyroid cancer	0.000109	0.000549	CbGpPWpGaD
Cladribine—SLC22A1—Transmission across Chemical Synapses—BRAF—thyroid cancer	0.000108	0.000543	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	0.000107	0.000537	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—PTEN—thyroid cancer	0.000104	0.000522	CbGpPWpGaD
Cladribine—PNP—Metabolism—PTGS2—thyroid cancer	0.000103	0.000519	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—CCND1—thyroid cancer	0.000103	0.000516	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—HPGD—thyroid cancer	0.000102	0.000511	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—TP53—thyroid cancer	0.000101	0.000506	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—HPGD—thyroid cancer	0.000101	0.000506	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—CCND1—thyroid cancer	9.85e-05	0.000495	CbGpPWpGaD
Cladribine—RRM2—Metabolism—RXRA—thyroid cancer	9.82e-05	0.000494	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—AKT1—thyroid cancer	9.68e-05	0.000487	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—HPGD—thyroid cancer	9.38e-05	0.000472	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	9.33e-05	0.000469	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	9.23e-05	0.000464	CbGpPWpGaD
Cladribine—DCK—Metabolism—RXRA—thyroid cancer	9.18e-05	0.000461	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	9.02e-05	0.000453	CbGpPWpGaD
Cladribine—PNP—Metabolism—PTEN—thyroid cancer	8.99e-05	0.000452	CbGpPWpGaD
Cladribine—SLC22A2—Neuronal System—BRAF—thyroid cancer	8.87e-05	0.000446	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	8.61e-05	0.000433	CbGpPWpGaD
Cladribine—SLC22A1—Neuronal System—BRAF—thyroid cancer	8.27e-05	0.000416	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—CCND1—thyroid cancer	7.85e-05	0.000395	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—RXRA—thyroid cancer	7.84e-05	0.000394	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—RXRA—thyroid cancer	7.76e-05	0.00039	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PPARG—thyroid cancer	7.53e-05	0.000379	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—RXRA—thyroid cancer	7.23e-05	0.000364	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—CCND1—thyroid cancer	7.02e-05	0.000353	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—TP53—thyroid cancer	6.76e-05	0.00034	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—TP53—thyroid cancer	6.49e-05	0.000326	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PPARG—thyroid cancer	6.2e-05	0.000312	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—AKT1—thyroid cancer	5.98e-05	0.000301	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PTGS2—thyroid cancer	5.92e-05	0.000298	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—TPR—thyroid cancer	5.84e-05	0.000294	CbGpPWpGaD
Cladribine—DCK—Metabolism—PPARG—thyroid cancer	5.79e-05	0.000291	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—TPR—thyroid cancer	5.78e-05	0.000291	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PRKAR1A—thyroid cancer	5.74e-05	0.000289	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PRKAR1A—thyroid cancer	5.68e-05	0.000286	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—TPR—thyroid cancer	5.39e-05	0.000271	CbGpPWpGaD
Cladribine—SLC22A2—Transmission across Chemical Synapses—HRAS—thyroid cancer	5.33e-05	0.000268	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PRKAR1A—thyroid cancer	5.3e-05	0.000266	CbGpPWpGaD
Cladribine—PNP—Metabolism—AKT1—thyroid cancer	5.18e-05	0.000261	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PTEN—thyroid cancer	5.16e-05	0.00026	CbGpPWpGaD
Cladribine—SLC22A1—Transmission across Chemical Synapses—HRAS—thyroid cancer	4.96e-05	0.00025	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—AKT1—thyroid cancer	4.95e-05	0.000249	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PTGS2—thyroid cancer	4.88e-05	0.000245	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—TP53—thyroid cancer	4.62e-05	0.000232	CbGpPWpGaD
Cladribine—DCK—Metabolism—PTGS2—thyroid cancer	4.56e-05	0.000229	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—SLC5A5—thyroid cancer	4.37e-05	0.00022	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—SLC5A5—thyroid cancer	4.33e-05	0.000218	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PTEN—thyroid cancer	4.25e-05	0.000214	CbGpPWpGaD
Cladribine—SLC22A2—Neuronal System—HRAS—thyroid cancer	4.08e-05	0.000205	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—SLC5A5—thyroid cancer	4.03e-05	0.000203	CbGpPWpGaD
Cladribine—DCK—Metabolism—PTEN—thyroid cancer	3.97e-05	0.0002	CbGpPWpGaD
Cladribine—SLC22A1—Neuronal System—HRAS—thyroid cancer	3.8e-05	0.000191	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—RXRA—thyroid cancer	3.67e-05	0.000185	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—RXRA—thyroid cancer	3.63e-05	0.000183	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—RXRA—thyroid cancer	3.39e-05	0.00017	CbGpPWpGaD
Cladribine—RRM1—Metabolism—AKT1—thyroid cancer	2.98e-05	0.00015	CbGpPWpGaD
Cladribine—RRM2—Metabolism—AKT1—thyroid cancer	2.45e-05	0.000123	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PPARG—thyroid cancer	2.32e-05	0.000117	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PPARG—thyroid cancer	2.29e-05	0.000115	CbGpPWpGaD
Cladribine—DCK—Metabolism—AKT1—thyroid cancer	2.29e-05	0.000115	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PPARG—thyroid cancer	2.14e-05	0.000108	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PTGS2—thyroid cancer	1.82e-05	9.17e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PTGS2—thyroid cancer	1.81e-05	9.08e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PTGS2—thyroid cancer	1.68e-05	8.46e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PTEN—thyroid cancer	1.59e-05	8e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PTEN—thyroid cancer	1.57e-05	7.92e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PTEN—thyroid cancer	1.47e-05	7.38e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—AKT1—thyroid cancer	9.17e-06	4.61e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—AKT1—thyroid cancer	9.07e-06	4.56e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—AKT1—thyroid cancer	8.46e-06	4.25e-05	CbGpPWpGaD
